Your session is about to expire
← Back to Search
ARD-501 for Autism
Study Summary
This trial investigates the safety of two doses of a medication in people with Autism Spectrum Disorder.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research looking for new participants at the moment?
"It seems that this clinical trial is no longer accepting participants. Initially posted on November 30th 2023, the last update was made on November 9th 2023. Nonetheless, there are still 321 other trials actively recruiting patients at present."
Is it possible for individuals under 30 years of age to participate in this therapeutic trial?
"For this clinical research, participants must be between 17 and 25 years of age."
Has the FDA granted authorization for Phase 1: Low Dose?
"Drawing from Phase 2 trial data, our team at Power has assessed the safety of Low Dose to be a score of two. This reflects that there is some evidence for safety but very little in terms of efficacy."
For what demographic is this clinical trial best suited?
"Patients with autism spectrum disorder who fall between the age bracket of 17 to 25 are eligible to participate in this medical study. Currently, 12 individuals need be recruited for the trial."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger